Karisma 2 Biopsy study on low-dose tamoxifen

Analyses are ongoing in the Karisma 2 Biopsy study. Karisma 2 Biopsy is a nested cohort within the Karisma 2 clinical trial on low-dose tamoxifen, conducted during 2017-2019 in Sweden. In all, 96 participants donated breast biopsied before and after treatment with tamoxifen or placebo. Analyses are ongoing and results are expected after the summer. 


Karisma 2 clinical trial on low-dose tamoxifen is completed

We have now completed the Karisma 2 randomised clinical trial on low-dose tamoxifen. In all, 1,440 women were included in the Swedish two-centre study, at Södersjukhuset in Stockholm and at Unilabs in Lund.  The results are being analysed and the first paper is expected to be published after the summer 2020.  Karisma-2 is a dose optimisation…


Papers on Mammographic Density Change and breast cancer

Doctoral student Shadi Azam has recently published two papers investigating mammographic density change using the KARMA cohort.


Karma Creme-1 end of study

The last participants have now ended their participation in Karma Crème-1 and the study is officially closed. Analyses are on-going and we are expecting to publish the results during the autumn 2019.


Inclusion to Karisma-2 now completed

We have now completed the inclusion of 1,440 women in the Karisma-2 double-blinded clinical trial at the breast centre at Södersjukhuset in Stockholm and …


KARISMA results: A nearly ten-fold descaling of tamoxifen have a potential treatment effect

The results from the 6-armed RCT trial KARISMA show that 2.5 mg of tamoxifen has the potential to be as effective in reducing incidence and recurrence of breast cancer as the established 20 mg dose.  Mammographic density change is a proxy for tamoxifen therapy response. We tested if lower doses of tamoxifen were non-inferior to…


A thesis based on the Karma Cohort and focusing on breast cancer risk prediction and prevention was defended 15 January, 2021

The thesis included a paper describing a unique tool, STRATUS, for measuring mammographic density regardless of type of image and vendor. This tool and additional mammographic features was used for generating a risk prediction tool and described below, published 20-09-08 (please see below). The thesis also described the Karisma trial where lower doses of tamoxifen…


A thesis based on the Karma Cohort and focusing on mammographic features was defended 11 December, 2020

Shadi Azam has published three papers (see links below) and have one paper in manuscript. Shadi has over the last years worked hard trying to understand the factors behind two mammographic “features” and how these features influence the risk of breast cancer. The features are mammographic density change and breast microcalcifications. None of them are currently particularly…


Karma starts new clinical trial on contrast enhanced mammography

Karma Kontrast is a randomised clinical trial conducted at the mammography unit at Södersjukhuset (Stockholm South General Hospital), Sweden, in collaboration with researchers at Karolinska institutet. The trial will study if contrast enhanced mammography can be used to improve mammography screening. Karma Kontrast is anticipated to go on until January 2022 and will enrol 420…


A short term risk model identifies women that will be diagnosed with breast cancer

Using the prospective screening Karma cohort, an image-based breast cancer 2-year risk model was developed using mammographic features (density, masses, microcalcifications) identified using artificial intelligence. The model could be extended by including a polygenic risk score with 313 single nucleotide polymorphisms. The area under the receiver operating characteristic curve (AUC) for the image-based model was…


Change in mammographic density do not seem to influence the risk of breast cancer

The association between annual mammographic density change and breast cancer risk was evaluated using the Karma Cohort (N = 43 810). Density was measured using the STRATUS method and relative mammographic density change was categorized as decreased (>10% decrease per year), stable (no change), or increased (>10% increase per year). Cox proportional hazards regression was…


Karma participants answer questionnaire about breast cancer risk communication

Around 62,000 Karma participants have recently received emails regarding strategies for breast cancer risk communication. The Karma group aim to collect questionnaire data from the Karma participants on whether they want to know about their individual risk of breast cancer, and if so, how and by whom the risk should be communicated to the women. …


Swedish media covers Karma CREME-1 study start

Earlier this month the Swedish national television (SVT) visited the Karma study center and met with professor Per Hall, principal investigator of Karma CREME-1 and other personal at the center. …


First participants enrolled in the Karma CREME-1 study

The Karma CREME-1 phase 2 clinical trial on topical endoxifen for preventive treatment of women with mammographic breast density is now open for inclusion. The study will include 90 participants and each participant will use topical endoxifen for six months. Preliminary results are expected during spring 2019. …


Karma clinical trial on topical endoxifen soon opens for inclusion

The Swedish Medical Products Agency (MPA) has approved a Phase 2 study of topical endoxifen for preventive treatment of women with mammographic breast density. …


Thesis on aggressive breast cancer based on the Karma study published

On the 23rd of February, Dr Johanna Holm defended her thesis entitled “Aggressive breast cancer: epidemiological studies addressing disease heterogeneity”, partly based on Karma samples. …


Karisma 2 clinical trial on tamoxifen for preventive use is halfway through

The Karisma 2 trial on dose optimisation of tamoxifen for preventive use has now reached 800 participants in Lund and in Stockholm and has thereby reached the halfway through milestone. Karisma 2 in expected to close the inclusion by December 2018.


Karma cohort part of novel discoveries of new genetic breast cancer risk variants

As part of international research consortium including Karma samples, 72 new gene variants that predispose to breast cancer have been identified through an analysis of genetic data from more than 275,000 women, whereof 146,000 with breast cancer. Many of the genes lie in regulatory, rather than coding regions, and some are specific for oestrogen receptor…


The first Karma based model for predicting risk of breast cancer has been published

One of the key aims of the Karma Project is to identify the women that eventually will be diagnosed with breast cancer. In collaboration with the Swedish mammography screening program we identified increased levels of mammographic density, microcalcifications and suspicious lumps in the breast as key factors for breast cancer risk. We created a risk…


Karma researcher identifies discontinuation of adjuvant hormone therapy as a major problem in breast cancer care

That adjuvant hormone therapy lowers the risk of breast cancer recurrence by approximately 40 per cent and breast cancer specific mortality with approximately 30 per cent has been shown in numerous studies. Proportion of women that stop taking their medication ranges from 20-70 per cent but few studies have addressed predictors of discontinuation of adjuvant…